This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
KalVista Pharmaceuticals Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de KalVista Pharmaceuticals de 60.3% y 27.5% respectivamente, mientras que el BPA crecerá en un 57.2% al año.
Información clave
60.3%
Tasa de crecimiento de los beneficios
57.19%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.7% |
| Tasa de crecimiento de los ingresos | 27.5% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 11 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • Apr 29
KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome
Summary KalVista Pharmaceuticals, Inc. is being acquired by Chiesi Group for $27/share in cash, valuing the company at $1.9 billion. KALV maintains a Strong Buy rating, driven by EKTERLY's $49.1M in 2025 sales and positive pediatric phase 3 KONFIDENT-KID interim results. EKTERLY is the first and only oral on-demand HAE therapy, with expansion into pediatric patients and multiple global markets underway. Key KALV risks include sNDA approval uncertainty for pediatric use, sustainability of EKTERLY sales, and successful Chiesi deal closure. Read the full article on Seeking Alpha
Nueva narrativa • Jan 23
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals develops oral therapies for hereditary angioedema, including EKTERLY for on demand treatment of HAE attacks. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Jan 10
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Sep 05
Is KalVista Pharmaceuticals (NASDAQ:KALV) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Jul 09
Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Artículo de análisis • Apr 02
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Dec 18
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
Summary NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. The company has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of 2027. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
KalVista: Upcoming PDUFA, But Not Without Risks
Summary KalVista's lead candidate, sebetralstat, has shown strong phase 3 results for on-demand treatment of HAE, with a PDUFA date set for June 17, 2025. Sebetralstat offers rapid symptom relief for acute HAE attacks, differentiating it from long-acting treatments like Navenibart and prophylactic options like Berotralstat. Financial concerns include a limited cash runway of three quarters, necessitating potential dilution for commercialization efforts post-approval. Despite promising data, competition from gene therapies and the shift towards prophylactic treatments make me cautious about investing in KalVista now. Read the full article on Seeking AlphaArtículo de análisis • Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 05
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Summary KalVista Pharmaceuticals, Inc. is advancing Sebetralstat, a potential first oral on-demand treatment for hereditary angioedema, with FDA approval expected in June 2025. Sebetralstat's successful Phase 3 trial and favorable safety profile position it to be a major player in the $900 million on-demand HAE market. Analysts are bullish on KalVista, with a recent Buy ratings and price targets ranging from $20 to $39 per share. KalVista has sufficient cash to fund operations into 2026, but may raise additional capital closer to the time around FDA approval. An analysis of KalVista Pharmaceuticals is presented in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 24
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Summary KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches. KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise. Sebetralstat could capture the $900 million on-demand HAE market and enhance its TAM to the $2.9 billion HAE market. Despite recent equity dilution, I believe KalVista's financials and regulatory progress make it a "buy" for new investors aware of biotech risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data for sebetralstat, with potential approval in early 2025. The financing of the commercialization of sebestralstat is still unclear, but KalVista now has many options for business development without diluting shareholders too much. The oral Factor XIIa product candidate is another interesting compound in indications with high unmet medical need that will be moved into clinic in 2024. Read the full article on Seeking AlphaArtículo de análisis • Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Artículo de análisis • Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Artículo de análisis • May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Oct 14
KalVista: Another Setback But The Key Value Driver Is Still In Place
Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the second half of 2023. Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. Although KalVista is funded beyond the next major milestones, the market does not attach value to the pipeline. KalVista once again shocks its shareholders with news regarding the termination of the KVD824 phase 2 trial. After its product candidate KVD001 failed to convince in a phase 2 study due to insufficient effectiveness a few years ago, safety concerns are the reason for the termination of the KVD824 trial. The news was very badly received by the market and, as a result, KalVista has lost more than 85% of its value since its peak following positive data on its product candidate Sebetralstat in 2021. Since Sebetralstat is apparently the main value driver of KalVista, and the developments in the pipeline do not allow any conclusions to be drawn about the latter, I wonder whether the high decline in the market capitalization of KalVista is justified. For me, the key value driver is still in place, meaning KalVista is significantly undervalued at current levels. In the following article, I want to introduce the company, explain my investment thesis and justify the potential of the value driver Sebetralstat. Business Of KalVista Pharmaceuticals KalVista (KALV) is a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing oral therapies for the rare disease hereditary angioedema ((HAE)). KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. HAE is a rare and potentially life-threatening disease, and despite the fact that there are several approved therapies, there is a high unmet medical need to improve the quality of life and ease of disease control. KalVista went public in 2016 through a reverse merger with Carbylan Therapeutics and raised $78.2 million at $17 per share in its first public offering in 2018. The Pipeline Looks Bigger Than It Is The origin of KalVista's pipeline lies in the deep understanding of plasma kallikrein inhibitors. Prior to the change in strategy to focus on developing therapies for HAE, the molecules were also being investigated for diseases in diabetic macular edema ((DME)). In summary, however, KalVista's research efforts have not been very successful in the past. Investors should currently focus on KalVista's lead product candidate, Sebetralstat, formerly known as KVD900, which is currently being investigated in a placebo-controlled Phase 3 trial as an on-demand therapy for HAE attacks. The results of the study are expected to be published in the second half of 2023 which, if positive, will form the foundation for a regulatory submission in the first half of 2024. Since there is already very strong and meaningful data from the Phase 2 trial, I think it is very likely that the success can be duplicated in the Phase 3 trial. The Phase 2 study in 53 HAE patients demonstrated with statistical significance both the clinical efficacy across all primary and secondary endpoints and the overall safety profile of Sebetralstat. The factor XIIa program clearly has great potential, but is still in preclinical development and investors should not assign a value to it at this time. In 2023, KalVista plans to file an investigational new drug application ((IND)) to move the program into human clinical trials. The factor XIIa program has tremendous potential in the prophylactic treatment of HAE. It targets an enzyme that plays a key role in HAE and could block the underlying cause of HAE attacks. If successful in a proof-of-concept study, the program could be expanded in other large market opportunities in the area of inflammation and thrombosis. Overview of Kalvista's pipeline (Company Presentation) KVD824 was investigated in a Phase 2 study for the prophylactic treatment of HAE. However, KalVista has terminated the study due to safety concerns, which indicate that KVD824 will no longer meet the requirements for a best-in-class oral prophylactic therapy. In the beginning, the DME program with its product candidate KVD001 generated a great deal of interest and resulted in a collaboration with Merck (MRK). Following disappointing Phase 2 data in which the primary endpoint was missed, Merck did not extend the collaboration. However, as a dose-dependent clinical benefit on vision has been observed in certain patients, KalVista is still evaluating how to proceed with KVD001. Financial Situation Following the last capital raise following the publication of the Phase 2 data of Sebetralstat at a price of $36 per share, KalVista is currently in a good financial position. With $142 million in cash and a cash runaway until at least 2024, KalVista is funded across key milestones and significant value drivers. With the recently announced termination of the KVD824 Phase 2 trial, an additional $3 million in research and development costs can be saved on a quarterly basis. In my opinion, investors should not fear dilution, as current prices do not reflect the value of Sebetralstat in any way. Nevertheless, I would like to mention that KalVista has access to an ATM with Cantor Fitzgerald, and can issue shares in the amount of $100 million. However, I expect a funding effort with the publication of Phase 3 topline data in the second half of 2023. At current prices, KalVista has a negative pipeline value of approximately $18 million. Consequently, despite the good Phase 2 trial results and the independence to KVD824, investors do not believe that Sebetralstat will be successful. KalVista is currently very attractively valued (Author's Chart) Investment Thesis An investor should always be clear on the reasons for investing in a company. Therefore, I will present my reasons why I believe KalVista is an attractive investment at current prices. KalVista currently has a negative pipeline value even though its lead product candidate is being investigated in a Phase 3 trial in an attractive orphan indication with high unmet medical need. In my opinion, an investment in KalVista given a negative pipeline value is a good opportunity to speculate on a data run in the second half of 2023. The HAE market is very attractive and KalVista has the opportunity to take market share from the established players with a differentiated and more convenient mechanism of action. Personally, I expect KalVista to reach a positive pipeline value of at least $200 million before data readout, which equates to at least $10 per share. Although much higher prices are certainly possible with positive data, I would like to limit my investment thesis to the data run at this time and reduce risk prior to the data release. The release of the data represents a binary event and carries tremendous risk. Even though the peer comparison below does not allow a complete comparison, one can still conclude that KalVista is undervalued based on current share prices. BioCryst (BCRX), with its approved oral drug for the prophylactic treatment of HAE, is a good example of KalVista's potential pathway with positive data. Even Astria (ATXS), which still owes proof-of-concept, currently has a higher pipeline valuation than KalVista. However, it should be noted that Astria is about to publish Phase 2 data, while KalVista has no catalysts scheduled for the next 12 months. Comparison of companies with oral HAE therapies. (Author's Chart) Market Outlook In HAE And Potential of Sebetralstat Having made my investment thesis clear, I want to justify why I attribute substantial value to Sebetralstat. The current standard of care provides both on-demand and preventive treatments. Overall, 6000-8000 patients are affected in the US and up to 15,000 patients in Europe, which translates into up to 100,000 annual attacks in the US and 150,000 in Europe. According to forecasts, the HAE market will show tremendous growth in the coming years, reaching 4.5 billion in 2027. The market will focus more and more on the prophylactic treatment, nevertheless patients will always need a back-up solution in case of an attack. Global HAE Treatment Market is Substantial and Growing (Astria Company Presentation) Currently, there are a number of approved products for HAE patients. The largest player in the HAE market is Takeda (TAK) with its product Takhzyro, which is administered subcutaneously every two weeks for prophylactic treatment. For on-demand treatment of HAE, Takeda offers Firazyr and Kalbitor as subcutaneous injections, generating in total approximately 50% of sales in the HAE market. Overall, the HAE market is very competitive and new product candidates are attracting very high interest. For example, in 2015, Shire (now Takeda) bought Dyax and its product candidate Takhzyro for $5.9 billion after robust Phase 1b data. HAE is a Meaningful and Growing Global Market (Pharvaris Company Presentation) Despite the large number of approved therapies, the HAE market continues to have a high unmet medical need. Except for the oral prophyhlactic drug Orladeyo, all therapies are administered by injection, which is generally less convenient for patients and reduces patient compliance. Injections present a hurdle for patients because, despite their effectiveness, they can cause pain at the injection site, are time-consuming to administer, and are difficult to store. All approved on-demand options have significant shortcomings. Early treatment improves outcomes but undertreatment and late treatment are common. Source: KalVista The barrier of using injections is also shown by studies. These show that less than 40% of all treated attacks are dosed within the first hour, and up to 45% of attacks weren't treated at all. These numbers prove that patients want new medicines that deliver on all fronts. People Living with HAE Desire HAE Therapy that can Deliver on ALL Fronts (Pharvaris Company Presentation) KalVista believes that its oral product candidate, Sebetralstat, has the potential to change the treatment paradigm for this disease. People living with HAE actively seek new products that demonstrate improvements in efficacy, safety and tolerability, and convenience. In addition, research with patient physicians and payers indicate that the drug profile of Sebetralstat could meet these requirements in case of positive study results. As a result, 93% of all patients said they could imagine switching to the oral product candidate Sebetralstat if approved. The benefits of Sebetralstat arise mainly from the fact that the drug is taken earlier due to the lower barriers. Patients should take the drug at the first sign of symptoms. Combined with the rapid uptake of the drug, Sebetralstat has the potential to stop the development of an attack at an early stage while symptoms are still mild and swelling is not severe. Early treatment of attacks leads to better overall disease management and prevention of attacks reaching the critical stage of significant swelling and discomfort. We therefore believe that a safe, oral on-demand treatment has the potential to become a preferred alternative for patients currently using injectable treatments. Source: KalVistaArtículo de análisis • Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 08
KalVista Pharmaceticals GAAP EPS of -$0.94
KalVista Pharmaceticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$0.94. Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.Seeking Alpha • Aug 22
KalVista reaches five-month high as rival tumbles on hereditary angioedema
The shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached the highest level since March on Monday after Pharvaris N.V. (PHVS), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121. An oral bradykinin B2-receptor antagonist, PHA121, is undergoing U.S. clinical studies in HAE under two Investigational New Drug (IND) applications for the rare inherited blood disorder. KalVista (KALV) is also advancing KVD900, its oral therapy for HAE, in a global late-stage trial with data expected in H2 2023. Even if PHVS resolves its clinical hold on its HAE candidate, the event will continue to be an overhang to a certain extent and “position KALV well if clinical data next year play out as we hope,” Stifel analyst Paul Matteis, who has a Buy rating and $32 on KALV wrote. Read: In April, Japanese pharma giant Takeda (TAK), a market leader in HAE, launched its Takhzyro injection for the condition in the U.S.Seeking Alpha • Jul 07
KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
KalVista Pharmaceticals press release (NASDAQ:KALV): Q4 GAAP EPS of -$0.98 beats by $0.11. Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal year is primarily due to increased operating expenses. “We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are meeting our enrollment targets for both our current clinical trials, the sebetralstat KONFIDENT Phase 3 and KVD824 KOMPLETE Phase 2. In addition, we are making great strides in developing our next wave of investigational compounds with promising preclinical data for our oral Factor XIIa inhibitor program. The Company is also well-capitalized, with funding until at least early 2024, which we expect takes us beyond data from both of our ongoing clinical trials.”Artículo de análisis • May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 435 | 120 | 118 | 278 | 3 |
| 12/31/2027 | 348 | 44 | 60 | 153 | 5 |
| 12/31/2026 | 213 | -69 | -58 | -34 | 6 |
| 3/31/2026 | 114 | -136 | -92 | -89 | N/A |
| 12/31/2025 | 74 | -164 | -125 | -122 | N/A |
| 7/31/2025 | 1 | -203 | -168 | -167 | N/A |
| 4/30/2025 | N/A | -183 | -154 | -153 | N/A |
| 1/31/2025 | N/A | -176 | -128 | -128 | N/A |
| 10/31/2024 | N/A | -156 | -123 | -123 | N/A |
| 7/31/2024 | N/A | -142 | -103 | -103 | N/A |
| 4/30/2024 | N/A | -127 | -90 | -89 | N/A |
| 1/31/2024 | N/A | -108 | -97 | -97 | N/A |
| 10/31/2023 | N/A | -101 | -79 | -78 | N/A |
| 7/31/2023 | N/A | -95 | -80 | -79 | N/A |
| 4/30/2023 | N/A | -93 | -76 | -75 | N/A |
| 1/31/2023 | N/A | -91 | -81 | -79 | N/A |
| 10/31/2022 | N/A | -92 | -86 | -84 | N/A |
| 7/31/2022 | N/A | -89 | -85 | -83 | N/A |
| 4/30/2022 | N/A | -82 | -79 | -78 | N/A |
| 1/31/2022 | N/A | -73 | -63 | -62 | N/A |
| 10/31/2021 | N/A | -61 | -57 | -56 | N/A |
| 7/31/2021 | N/A | -52 | -45 | -44 | N/A |
| 4/30/2021 | N/A | -46 | -30 | -30 | N/A |
| 1/31/2021 | 4 | -38 | -32 | -32 | N/A |
| 10/31/2020 | 5 | -37 | -37 | -37 | N/A |
| 7/31/2020 | 9 | -33 | -37 | -37 | N/A |
| 4/30/2020 | 13 | -29 | -45 | -45 | N/A |
| 1/31/2020 | 12 | -31 | N/A | -43 | N/A |
| 10/31/2019 | 14 | -26 | N/A | -40 | N/A |
| 7/31/2019 | 16 | -23 | N/A | -41 | N/A |
| 4/30/2019 | 16 | -21 | N/A | -36 | N/A |
| 1/31/2019 | 18 | -13 | N/A | -32 | N/A |
| 10/31/2018 | 16 | -14 | N/A | 7 | N/A |
| 7/31/2018 | 12 | -16 | N/A | 9 | N/A |
| 4/30/2018 | 8 | -16 | N/A | 11 | N/A |
| 1/31/2018 | 4 | -19 | N/A | 14 | N/A |
| 10/31/2017 | 2 | -22 | N/A | -26 | N/A |
| 7/31/2017 | 1 | -21 | N/A | -23 | N/A |
| 4/30/2017 | 2 | -21 | N/A | -24 | N/A |
| 1/31/2017 | 2 | -23 | N/A | -23 | N/A |
| 10/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 7/31/2016 | 2 | -18 | N/A | -15 | N/A |
| 4/30/2016 | 2 | -15 | N/A | -13 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que KALV sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que KALV sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que KALV sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (27.5% al año) de KALV crezcan más rápidamente que los del mercado US (13.5% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (27.5% al año) de KALV crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de KALV se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/12 09:37 |
| Precio de las acciones al final del día | 2026/06/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
KalVista Pharmaceuticals, Inc. está cubierta por 4 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | BTIG |
| Maurice Raycroft | Jefferies LLC |
| Serge Belanger | Needham & Company |